All News

According to investigators, the lack of anti-tumor activity and immunogenicity results do not support the agent’s further development in metastatic CRPC.

Ongoing studies are evaluating teclistamab-based regimens in the frontline setting as well as smoldering multiple myeloma, according to Surbhi Sidana, MD.

The FDA has assigned a PDUFA date of August 30, 2026, for approving ropeginterferon alfa-2b-njft among adults with essential thrombocytopenia.

A potential FDA approval of teclistamab/daratumumab would offer a “highly effective” option in multiple myeloma.

Data from the phase 3 MajesTEC-9 trial support teclistamab as an essential therapy for patients with multiple myeloma as early as first relapse.

A disease control rate of 100% was attained among 4 patients with Waldenström lymphoma treated with the CAR-NK cell therapy.

Federal cuts to insurance and cancer research could reduce access to therapies and stifle progress when incidence is rising across many common cancers.

Data from the QUILT-3.032 trial supported the Saudi approval of nogapendekin alfa plus BCG in adults with BCG-unresponsive NMIBC with carcinoma in situ.

Patients with BPDCN who did not achieve a complete or clinical complete response during treatment experienced a restoration of hematopoiesis.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

Data from the QUILT-3.055 and QUILT-2.023 studies support the accelerated approval of the nogapendekin alfa inbakicept regimens in Saudi Arabia.

No grade 3 or greater treatment-related adverse effects or long-term safety signals emerged with gemogenovatucel-T in this ovarian cancer group.

Investigators will submit detailed results from the QUILT-2.023 and QUILT-3.055 trials for peer-reviewed publication and future scientific presentations.

Next steps in surgery for gastroesophageal cancer include offerings for patients with advanced disease, such as those with oligometastases.

Data from the phase 1/2 EVICTION study support the breakthrough therapy designation for ICT01 plus venetoclax/azacitidine in acute myeloid leukemia.

Osimertinib plus chemotherapy improved overall survival across various subgroups in the phase 3 FLAURA2 trial, including those with CNS metastases.

Data from the GALAXY study in Japan may inform future use of total neoadjuvant therapy among patients with rectal cancer in the US.

Any-grade AEs were comparable between cadonilimab and a PD-1 monoclonal antibody regimen in this population, and no difference in grade 3/4 AEs emerged.

The complicated nature of gastroesophageal cancer underscores the importance of collaboration between teams to safely treat patients with the disease.

Ash Tewari, MBBS, hopes that with institutional partner aid, in 10 years, 1 million men will undergo prostate cancer screening through mobile units.

Researchers highlight the importance of geriatric assessments and patient-centered outcomes to manage unique physiological and functional challenges in older breast cancer survivors.

Bodies like the NCCN must keep up with data related to ctDNA so that it can be incorporated in a measured manner, said Nicholas Hornstein, MD, PhD.

The acceptance of the application is based on phase 3 MANEUVER study findings, in which pimicotinib improved responses vs placebo in this group.

Data from the phase 3 HARMONi trial support the application for the ivonescimab regimen in this EGFR-mutated NSCLC population.

Described as a “doctor’s office on wheels,” the mobile unit is equipped with Wi-Fi and includes point-of-care PSA/imaging tests to help bring care to patients.

Circulating tumor DNA may particularly help adjuvant treatment decision-making in stage II colon cancer, according to Nicholas Hornstein, MD, PhD.

The Million Strong Men Initiative is aimed at men at risk for prostate cancer who may be experiencing barriers to health care access.

The FDA no longer considers the phase 3 ALLELE trial adequate to support the approval of tabelecleucel for patients with EBV-positive PTLD.

The safety profile of atezolizumab plus bevacizumab and chemotherapy in this phase 3 trial was comparable with prior reports of the agents.

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.